Check out today's top analyst calls from around Wall Street, compiled by The Fly.

DEUTSCHE CAUTIOUS ON AUTO SECTOR: Deutsche Bank analyst Emmanuel Rosner initiated coverage of the auto sector with a cautious view. Rosner said this view reflects "cyclical and macro risks for the industry across the globe, as well as secular pressure from the shift towards electrified vehicles and autonomous shared mobility." The analyst favors suppliers with "secular growth potential through adoption of their technology," and as such, initiated Aptiv (APTV) and BorgWarner (BWA) with Buy ratings. Rosner also saw value in "suppliers that can maintain organic growth through share gains or favorable end-markets, and have favorable operational track record," and as such, initiated Dana Inc (DAN) and Lear Corporation (LEA) with Buy ratings. The analyst also started General Motors (GM) and Ford (F) with Buy ratings, citing "large potential upside from restructuring and portfolio decisions, favorable product mix and cycle, and value optionality from their efforts in Mobility." Rosner said he was negative on stocks facing secular pressure or market share loss, adding that he sees downside risk in Autoliv (ALV) and Veoneer (VNE), which he initiated with Sell ratings.

TESLA INITIATIONS: As part of the auto coverage, Deutsche Bank's Rosner started Tesla (TSLA) with a Hold rating and $375 price target. Rosner said Tesla's strong Q3 results demonstrated a "large improvement in manufacturing execution and profitability." The analyst believes this positive momentum is sustainable in the near/mid-term as the "major manufacturing bottlenecks appear to be resolved and demand has shown little evidence of trailing off." He does not see major competition for Tesla until 2020/2021, leaving Tesla in a "league of its own" through at least mid-2020. However, Rosner called Tesla's autonomous driving technology more uncertain, and has concerns for the stock longer term once the company fills its Model 3 pipeline.

Separately, Wedbush analyst Daniel Ives initiated coverage of Tesla with an Outperform rating and $440 price target. The company has the "most impressive product roadmap out of any technology/auto vendor around," Ives wrote in a research note. Ives believes Tesla will be a "game changing" driving force for the electric-vehicle transformation over the next decade. Further, Tesla has a "golden opportunity" to ramp Model 3 sales in 2019, said the analyst. He believes the "rollercoaster ride" of Model 3 production is "turning the corner."

GOLDMAN CUTS WALGREENS TO SELL: Goldman Sachs analyst Robert Jones downgraded Walgreens Boots Alliance (WBA) to Sell from Neutral and lowered his price target for the shares to $68 from $73. The analyst said he struggles to make a "compelling fundamental case" for the Americas Healthcare Services Supply Chain heading into 2019 as "issues facing core growth drivers do not seem to be abating." Jones sees limited "core" growth for the large-cap names amid persisting sales and margin pressures and as drug pricing remains a regulatory focus. He downgrades Walgreens to Sell saying challenges in its retail pharmacy business "have intensified, forcing the company to search for other avenues of growth." Jones also kept a Neutral rating on CVS Health (CVS) and Sell rating on Rite Aid (RAD).

H.C. WAINWRIGHT UPGRADES BAUSCH TO BUY: H.C. Wainwright analyst Raghuram Selvaraju upgraded Bausch Health Companies (BHC), the company formerly known as Valeant Pharmaceuticals, to Buy from Neutral and raised his price target for the shares to $58 from $25. Now is an "appropriate time to become more bullish on the story," Selvaraju said. The analyst sees "continued evidence" that Bausch's organic growth should have a substantial impact on the company's debt-to-EBITDA ratio, and thus make it a less leveraged company. The market has "underrated and underappreciated the tuck-in and complementarity-driven developments" of the past several months, which have gradually begun to position Bausch Health more strongly in several core markets, said Selvaraju. The analyst points to the launches of Altreno and Bryhali and the inclusion of Doptelet, a drug complementary to Xifaxan.

BAIRD UPGRADES LATTICE TO OUTPERFORM: Baird analyst Tristan Gerra upgraded Lattice Semiconductor (LSCC) to Outperform from Neutral and raised his price target for the shares to $9 from $6. Lattice has a highly defensible business model, in need of improved execution, Gerra said. He thinks the right management team is now in place to "unlock value with a credible turnaround strategy." The implementation of cost controls, gross margin expansion and improving revenue comps represent stock catalysts in 2019, said Gerra. He said Lattice becomes his firm's top small-cap idea for 2019.

GOLDMAN UPGRADES REGENERON TO BUY: Goldman Sachs analyst Terence Flynn upgraded Regeneron Pharmaceuticals (REGN) to Buy from Neutral and added the shares to his firm's Americas Conviction List. The analyst sees 25% upside after boosting his price target for the shares to $472 from $415. Regeneron's pipeline is a "call option" and its competitive risks are generally priced in at current share levels, Flynn said. The analyst says results from Goldman's recent wet age-related macular degeneration/diabetic macular edema survey support his longer-term Eylea market share loss assumptions and provides comfort that the competitive risk is generally priced in. Further, he sees upside to Dupixent consensus estimates in 2019.

NOMURA CUTS CISCO TO NEUTRAL: Nomura Instinet analyst Jeffrey Kvaal downgraded Cisco Systems (CSCO) to Neutral from Buy with an unchanged price target of $50. Strengthening information technology spending, an innovation-led refresh cycle, and a rising software mix have lifted Cisco's multiple and its shares to post-recession highs, Kvaal wrote in a research note partially titled "Well Understood Story." However, the analyst believes "some tailwinds," notably IT spending strength, may reverse in 2019 "to reveal imperfections in Cisco's story." In short, Kvaal expects Cisco to "fire on fewer cylinders in 2019."